PMC6301300_01
Chest X-ray and CT scan before treatment with ceritinib.
ott-12-015Fig1.jpg
PMC6301300_01_ott-12-015Fig1.jpg
f1-ott-12-015
Prior to the third line of chemotherapy, the patient was weakened with the ECOG-PS 3 because of anorexia, dyspnea, dysphagia, and cachexia (Figure 1).
CT scan before introducing ceritinib (A, C), and 6 weeks after treating with ceritinib (B, D). Reduction of the primary tumor and plural effusion was revealed after the treatment.
ott-12-015Fig2.jpg
PMC6301300_01_ott-12-015Fig2.jpg
f2-ott-12-015
Abdominal metastatic lymph node also decreased in size and was assessed as showing partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) for at least 2 months (Figure 2A-D).